Imagion Biosystems Limited is pleased to announce that it has received its 2020 R&D tax incentive claim of $2,612,159 from the Australian Taxation Office.
This is higher than the $2,197,028 received in respect of the 2019 claim and reflects increased R&D spend in 2020 as the Company undertook preparatory activities towards the first-in-human trial of its MagSense® imaging technology in HER2 positive breast cancer patients.
See the announcement.
Highlights: Announced positive results from IBI10103 Phase I Study demonstrating safety and clinical feasibility of molecular MRI with MagSense® HER2 Imaging Agent Presented new animal
MELBOURNE and SAN DIEGO — Imagion Biosystems Limited (ASX: IBX), a company dedicated to improving healthcare through the earlier detection of cancer, announced that the
https://youtu.be/LI18OcgM9XM Imagion Announces Positive Results from IBI10103 Phase I Study Demonstrating Safety and Clinical Feasibility of Molecular MRI with MagSense® HER2 Imaging Agent Imagion Biosystems
We’re on a mission to make cancer more detectable.
Imagion Biosystems (IBX) is an innovative medical imaging company that uses bio-safe magnetic nanoparticles to detect cancer and other diseases.
Stay informed about our latest news and developments.
© Imagion Biosystems, Ltd. All Rights Reserved | Privacy Policy | Terms & Conditions | Careers | Corporate Governance